Respiratory Virus Vaccines: Pathways to Recommendations and Enhanced Coverage for At-Risk Populations
Authors:
Open Access
- 30 December 2024
- journal article
- research article
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 14 (S1) , 99-114
Abstract
While marked differences exist between influenza virus, respiratory syncytial virus (RSV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is substantial overlap in the vulnerability of populations most at risk for severe disease following infection, chief among them being advanced age, multiple comorbidities, and immunocompromise. Vaccination is an established and effective preventative strategy to protect against respiratory viral infections (RVIs), reducing morbidity and mortality, minimizing the potential for long-term complications, and mitigating exacerbation of existing health conditions. Despite the demonstrated benefits of immunization throughout the life course and recommendations by health authorities, coverage rates of at-risk populations against vaccine-preventable diseases remain suboptimal and vary considerably by country and demographic strata. The objective of this supplement’s concluding article is to discuss the current barriers to vaccination and strategies to enhance coverage against RVIs among adult at-risk populations. Identified barriers include low awareness of the risks of vaccine-preventable diseases, low perceived benefits of vaccination, and doubts regarding vaccine safety, which together contribute to vaccine hesitancy. Additionally, logistical issues related to vaccine supply, access, and costs present further challenges in achieving optimal coverage. Potential strategies to overcome these barriers and improve uptake include strengthening and harmonizing immunization guidelines and improving respiratory disease surveillance systems to appropriately identify needs and direct resources. Co-administration or use of combination vaccines against multiple viruses may be a viable strategy to enhance coverage by simplifying schedules and improving access, together with future utilization of enhanced vaccine platforms to develop novel vaccines. In addition, vaccination-focused healthcare provider training and consumer education are recommended to address vaccine hesitancy. Reaching vaccination targets and expanding coverage in adult at-risk populations are increasingly achievable with the availability of new and updated vaccination strategies for respiratory viruses, but will require collective efforts across providers, policymakers, scientists, health officials, and the general population.Keywords
This publication has 51 references indexed in Scilit:
- Deadly places: The role of geography in Aboriginal and Torres Strait Islander COVID-19 vaccinationAustralian and New Zealand Journal of Public Health, 2024
- Cost-Related Barriers and Ensuring Equitable Access to Vaccines in the USJAMA Pediatrics, 2023
- Social determinants of health and vaccine uptake during the first wave of the COVID-19 pandemic: A systematic reviewPreventive Medicine Reports, 2023
- Understanding the rebound of influenza in the post COVID-19 pandemic period holds important clues for epidemiology and controlInternational Journal of Infectious Diseases, 2022
- Supporting immunization programs to address COVID-19 vaccine hesitancy: Recommendations for national and community-based stakeholdersVaccine, 2022
- Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysisInternational Journal of Infectious Diseases, 2021
- Disparities in COVID-19 Outcomes by Race, Ethnicity, and Socioeconomic StatusJAMA Network Open, 2021
- Attitudes and perception of influenza vaccines among older people in Singapore: A qualitative studyVaccine, 2019
- Primary care physicians’ perspectives on respiratory syncytial virus (RSV) disease in adults and a potential RSV vaccine for adultsVaccine, 2019
- Vaccine hesitancy: Definition, scope and determinantsVaccine, 2015